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Acute inflammatory demyelinating peripheral neuropathy (Guillain-
Barre-Syndrome) is by far the most common cause of immune-medicated
peripheral nervous system disease in children; with the near disappearance
of poliomyelitis, GBS is responsible for the great majority of cases of
acute flaccid paralysis. So far, in several controlled studies, corticosteroids,
plasmapheresis and IVIG have been utilized in pediatric patients, afflicted
with GBS. Regarding IVIG therapy, two methods have been used; the
high dose (1 gr/kg/day for 2 days), and the low dose (400mg/kg/day for
5 days). Review of literature shows that a faster rate of recovery can be
accomplished in patients who receive total dose of IVIG in 2 days as
compared to the dose being given over 5 days.
Materials & Methods:
 In this study we have compared these two types of treatment in an
investigation, conducted in the Mofid Children Hospital on pediatric
patients who had sudden onset of acute flaccid paralysis, and were
diagnosed as having GBS. Based on histories, physical examination and
electrodiagnosis, subjects were divided in two groups, the high dose
IVIG treatment, 1gr/kg/day for 2 days (experimental group), and the low
dose IVIG treatment, 400 mg/kg/day for 5 days (control group). Statistical
analyses were then carried out using the appropriate software.
Results:
 Result of this study showed a faster rate of recovery for patients in the
high dose IVIG group; in this group duration of weakness of limbs was
shorter and returning of DTR was faster than in controls. In fact, in this
type of treatment, the relationship between high dose IVIG therapy and
drug side effects was not significant.
Conclusion:
 Base upon the finding in the present study, we conclude that the high
dose IVIG therapy is superior to low dose, in view of faster duration of
recovery and shorter hospital stay.
Also we may infer that shorter hospital stay could be a factor in reducing
of more nasocomial infection.
In conclusion, we suggest using high dose IVIG treatment of choice in
GBS.
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HIGH AND LOW DOSE IVIG THERAPY IN GUILLAIN-
BARRE-SYNDROME CHILDREN: A COMPARISON
Introduction
The Guillain Barre’ syndrome (GBS), a post infectious
poly neuropathy,  is by far the most common cause of
immune- mediated peripheral nerve disease in children;
with the near disappearance of poliomyelitis, this is
responsible for the majority of cases of acute flaccid,
paralysis. (1, 2, 3)
The first cases were recorded in 1859 by Landry, who
noted that the disorder produces both motor and sensory
symptoms, especially the former, which involves the
distal parts of the limbs. Guillain, Barre and Strohl stressed
the presence of albuminocytologic dissociation, of CSF
in this condition.
GBS consists of four subgroups:
1. Sporadic GBS, the most common, (85% to 90%)
(Acute inflammatory demyelinating peripheral
neuropathy-AIDP)
2. Acute motor sensory axonal neuropathy (AMSAN)
3. Miller fisher syndrome
4. Chronic inflammatory demyelinative peripheral
neuropathy (CIDP)
Characteristically it is symmetric. A prodromal respiratory
illness or gastroenteritis occurs in approximately two-
third of the patients. Elevation in the CSF protein content
is typical, exceeding 45mg/dl in 88% of affected children;
CSF cell count is usually normal and the EMG-NCV
shows conduction block. (1, 2, 3)
Since GBS is the most common cause of acute flaccid
paralysis in children, several large controlled studies
have been conducted to determine the most effective
therapies in pediatric patients. In clinical practice today,
Plasmapheresis, IVIG and corticosteroids are routinely
used, of which, IVIG treatment is safer and less traumatic
for children. High dose IVIG1 is another effective means
of treating GBS. In this study we have assessed the use
of high dose IVIG in the treatment of GBS patients,
believing that it can be more effective than low dose IVIG2
therapy. (1, 2, 3, 8, 9, 10) this method of treatment shortens
the hospital stay and is consequently less expensive for
patients (5, 6, 7).
Considering the fact that GBS is today the most common
cause of acute flaccid paralysis in children in our country,
and in view of the lack of any literature comparing the
two types of treatments (high dose vs. low dose IVIG),
this study was conducted to determine which is more
effective.
Materials and Methods
 Subjects were 50 children presenting with the chief
complaint of acute flaccid paralysis, to the pediatric
neurology department of the Mofid childrens’ hospital;
all patients were admitted and appropriate investigations
(history, physical examination, laboratory analyses and
EMG-NCV) were carried out.
Only children with acute inflammatory demyelinating
polyneuropathy were included in our study and those
with acute motor-sensory axonal neuropathy, acute motor
axonal neuropathy and Miller Fisher syndrome were
excluded . Eventually our patients were randomly divided
into 1-High dose IVIG treatment or experimental group
(25 patients), and 2- Low dose IVIG treatment or control
group (25 patients); the children were matched for age,
sex, and grade of illness. SPSS and statistical software
were used for analysis of data obtained.
Scaling:
To evaluate the severity of illness, 5 grades for GBS
were defined:
Grade 1: Force of distal lower extremities 3/5
Force of proximal lower extremities 4/5
DTR of lower extremities decreased
DTR of upper extremities normal
Gag reflex, crying, phonation and swallowing 
             normal
Grade 2: Force of distal lower extremities 3/5
Force of proximal lower extremities 3/5
Force of distal upper extremities 4/5
Force of proximal upper extremities 4/5
DTR of upper and lower extremities decreased
             (especially in lower E.)
Gag reflex, crying, phonation and swallowing
             normal
Grade 3: Force of proximal lower extremities 3/5
Force of distal lower extremities 2/5
Force of proximal upper extremities 4/5
Force of distal upper extremities 3/5
DTR of upper extremities decreased
DTR of lower extremities decreased or absent
Gag reflex decreased, crying and phonation weak
             and swallowing normal
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1-High dose IVIG means I gr/kg/day for 2 days
2- Low dose IVIG means 400mg/kg/day for 5 days
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Grade 4: Complete flaccid paralysis in lower extremities
Force of distal upper extremities below 2/5
Force of proximal upper extremities below 3/5
DTR of upper extremities one plus (+)
DTR of lower extremities absent
Gag reflex decreased, crying weak
Mechanical ventilation needed during hospital stay.
Grade 5: Complete flaccid paralysis in upper and lower extremities (flaccid quadriplegic)
DTR of upper and lower extremities absent
Gag reflex absent
Aphonic
Needs immediate mechanical ventilation
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Results:
In the experimental group, the youngest patient was 8 months old and the oldest one 13 years (peak age between 2-
5 years old). Among the controls, the youngest patient was 15 months and the oldest 14 years (peak age between 2-
5 years old).   (Table 1)
In the experimental group, 4 patients were female and 21 were male. In the control group, 5 were female and 19 male.
Our study had a 5:1 male: female ratio, whereas other studies this ratio was 3:2 or 3:1 (table2).
Table 1: Frequency of age in experimental and control groups
Table 2: Frequency of sex in experimental and control groups
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All patients (experimental and control) fell into grades
II, III, IV and V
Grade II: In grade II we had 10 patients (3 female and
7 male) in the experimental group and 11 patients (4
female and 7 male) in the control group. Bed /day time
in the experimental group was under 5 days in 3 patients,
between 5-9 days in 8 patients, and in 3 was 10-15 days.
Duration of weakness in this group in lower extremities
was 2-5 days in 7 patients and between 5-10 days in 3
patients. For controls, this duration was between 5-10
days in 10 patients and in 1 patient was over 10 days.
In all patients in the experimental group, duration of
weakness in upper extremities was between 2-5 days and
in all the controls this was between 5-10 days.
Duration of decreased, or absence of, DTR in lower
extremities in the experimental group was 2-5 days in 9
patients, and between 5-10 days in one patient; in control
group however this duration was between 5-10 days in
one patient and over 10 days in 10 patients.
Duration of decreased DTR in upper extremities in the
entire experimental group was between 5-10 days, the
time being 5-10 days in one patient of the control group
and over 10 days in 10. No super imposed infections or
drug side effects were observed in grade II.(tables 3-11)
Grade III: In grade III, we matched 7 patients from the
experimental group with 8controls. In this grade all
patients in the experimental and control groups were
male. Bed/day time in all patients of the experimental
group was 5-9 days, while for the controls, it was between
5-9 days in 3 patients and between 10-15 days in 5.
Of 7 patients in the experimental group, 5 patients had
normal(or mildly decreased)  gag reflex at admission, 2
of the patients this reflex was decreased and  after
treatment, the reflex became normal, without any need
or  mechanical ventilation. In 8 patients of the control
group, 7 had normal gag reflex at admission, while 1
patient had reduced gag reflex, requiring mechanical
ventilation. Duration of weakness in the lower extremities
of 6 patients in the experimental group was between 2-
5 days, while in one it was 5-10 days. In all of the controls,
this duration lasted between 5-10 days. Duration of
weakness in the upper extremities in the experimental
group was between 2-5 days, being 2-5 days in 2 patients
of the control group and between 5-10 days in 6. The
duration of decreased or absence of DTR in lower
extremities in the experimental group was between 2-5
days in 5 and 5-10 days in 2 patients; in all in the controls
this duration was over 10 days. Decreasing in the upper
extremities in all individuals of the experimental group
took 5-10 days and in all of the patients in control group
was more than 10 days.(Tables 3-11)
Grade IV: 4 patients (3 male, 1 female) of experimental
group were matched to 3 of the controls (2 male, 1
female). Bed/day time in one patient of the experimental
group was between 5-9 days, while in the controls, this
duration was10-15 days in 2 patients and over 15 days
in one. In the experimental group, 4 patients had decreased
gag reflex and following treatment, in 3 patients this
condition normalized in 2 days, without any need for
mechanical ventilation. In 1 patient however, who did
need mechanical ventilation this reflex returned in 2-5
days. In 3 of the controls, 2 needed mechanical ventilation,
their gag reflex returning in 2-5 days; in the third child,
gag reflex returned spontaneously in less than 2 days.
The duration of weakness in lower extremities in the
experimental group was between 2-5 days in one patient
and between 5-10 days in 3 patients, while in the controls,
in 2 patients this was between 5-10 days and in one
patient was over 10 days. Duration of weakness in the
upper extremities in all patients of the experimental group
lasted 2-5 days, whereas in 2 of the controls this duration
was between 2-5 days in one. Duration of decreased, or
absence of, DTR in lower extremities in all 4 patients of
the experimental group was between 5-10 days, while it
was over 10 days in all the controls of this grade.
The duration of decreased, or absence of, DTR in upper
extremities in all 4 patients of the experimental group
was between 5-10 days, but lasted over 10 days in 3 of
the controls. There was no occurrence of either
superimposed infections or any drug side effects in
any patients of groups II, III, or IV.(tables 3-7)
Grade V: All those classified as GBS grade V, were
matched for degree of weakness, age and sex; these
included 4 patients of the experimental group and 3
controls, all males. Bed/day time in the experimental
group in 3 patients was 5-9 days, while one patient stayed
for 14 days. Upon admission, all patients in the
experimental and control groups had decreased gag reflex,
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for which they were transferred to ICU and connected to mechanical ventilation. Of 4 patients in the experimental
group, 2 had gag reflex  of four paitents in experimental group,two oh them had gag reflax after 2 days whereas in
other 2 patients, this reflex returned within 2-5 days. Of the 3 controls, in one gag reflex returned in 5 days and in
the other two it returned after7 days. While the duration of weakness in the lower extremities of 4 patients in the
experimental group lasted 5-10 days, in the 3 controls of this grade it was over 10 days. Duration of weakness in the
upper extremities in all patients of experimental group was between 2-5 days, being between 5-10 days in all controls
of this grade. Duration of decreased, or absence of, DTR in the upper extremities in all individuals of the experimental
group was 5-10 days, while in the corresponding controls it was over 10 days. Complications related to super imposed
infection occurred in 2 individuals of the experimental group, whereas all 3 controls in this grade were affected by
this problem. Symptoms of fever were observed in patients suffering from infection, but these were not related to
any side effects. No patients complained of headache or vomiting, except for one control, who developed high blood
pressure while receiving assisted ventilation, and was treated with Diazoxide.(table 3-11)
Discussion
Hospital stay in patients receiving high dose IVIG treatment (experimental group) was shorter than low dose IVIG
treatment (controls). The relationship between high dose IVIG therapy and the shorter bed/day time was significant.
(Table 4)  P<0.05 (P=0.0198). Our findings are similar to those of other studies (4,5).
Table 3: Frequency of grading in experimental and control groups
Table 4: Frequency of bed/day time in experimental and control groups
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Of 10 patients with decreased gag reflex in the experimental group, 5 needed mechanical ventilation, while in 5 others,
this reflex returned with just drug therapy without any need for assisted ventilation (Tables 5,6). Of 7 controls with
decreased gag reflex, 6 had to have mechanical ventilation, while only one recovered with just continuation of drug
therapy (Tables 5,6).
The relationship between time of returning of gag reflex and the type of treatment (high dose /VS/ low dose IVIG)
was not statistically significant (P=0.1544) (Table 6)
Duration of weakness of lower extremities was much shorter in patients, were given high dose IVIG therapy. (Table
7) (P<0.0001); this finding corresponds with the results of other studies (4-7).
Table 5: Frequency of need for mechanical ventilation in experimental and control groups
Table 6: Frequency of gag reflex return in experimental and control groups
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Similar results were obtained for the in upper extremities; duration of weakness in arms was remarkably shorter in
those patients who received high dose IVIG (Table 8) (P<0.0001). These results are in agreement with those obtained
in other studies (4,5).
In patients receiving high dose IVIG therapy, the duration of decreased, or absence of, DTR in both upper and lower
extremities was significantly shorter (table 9-10) (P<0.0001); findings correlate with studies from other countries
(4,5,6).
Table 7: Frequency of duration of weakness in lower extremities in experimental and control groups
Table 8: Frequency of duration of weakness in upper extremities in experimental and control groups
Table 9: Frequency of decreased, or absence of, DTR in lower extremities in experimental and control groups
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-All patients with super imposed infection, (in both the experimental and control groups) had to be transferred to ICU,
needing mechanical ventilation. Since no nosocomial infection was found in other patients, the relationship between
superimposed infection and the type of treatment (high dose or low dose IVIG) was not significant (Table 11) (6)(P
=1)
Fever was seen only in patients suffering from superimposed infections; it was not a side effect of the drugs.
Table 10: Frequency of duration of decreased, or absent, DTR in upper extremities in
experimental and control groups
Table 11: Frequency of drug side effects in experimental and control groups
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 The relationship between fever and the type of treatment
(high dose or low dose IVIG therapy) was not significant
(Table 11) ( P=1); Other studies have not reported any
complications and drug side effects(6).
The relationship between the type of treatment (high
dose or low dose IVIG therapy) and hypertension (drug
side effect) was not significant (Table 11) (6).
Five patients of grade V (3 control, 2 experimental), who
suffered superimposed infection had to be transferred to
ICU, needing mechanical ventilation; the infectin,
nasocomial in nature, was not observed in the other
grades, and the relationship between superimposed
infection and the type of treatment was not significant
(Table 11).
Conclusion
Based on the findings of the present study, we conclude
that in view of shorter duration of recovery and reduced
hospital stay, high dose IVIG therapy is superior to the
low dose one; apparently the reduction in time of hospital
stay prevented further occurrence of cases of nosocomial
infections.
Also, duration of weakness in both upper and lower
extremities was significantly shorter in the group of
patients receiving high dose IVIG therapy. Lastly no
association was found between drug side effects and type
of treatment. (High dose/VS/Low dose)
In conclusion we highly recommend high dose IVIG
treatment as the treatment of choice in children with GBS
syndrome.
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